MedTrace Logo

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

NCT01768858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2019-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's disease (CD) and ulcerative colitis (UC) patients' adherence attitudes (beliefs) to maintenance therapy with adalimumab monotherapy or combination therapy with methotrexate (in participants with RA) and to investigate whether there were correlations between such beliefs and adherence to maintenance treatment.

Conditions

Interventions

DRUG

Adalimumab

Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen

Sponsors & Collaborators

  • Raffeiner GmbH

    collaborator INDUSTRY

  • AbbVie

    lead INDUSTRY

Principal Investigators

  • Alexander P Dorr, PhD · AbbVie Austria

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-05
Primary Completion
2017-08-13
Completion
2017-08-13

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768858 on ClinicalTrials.gov